Indivior PLC (NASDAQ:INDV) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Indivior, with six buy ratings and one hold rating. The average 12-month price target is $45.17, above the stock’s reported $34.88 price.
• Indivior reported quarterly revenue of $343 million and EPS of $5.75, while analysts expect full-year EPS of $3.66. The stock has a market capitalization of approximately $4.12 billion and recently traded down 2.3%.
• The company announced a special $8.13 dividend payable November 6 to shareholders of record October 30. Institutional investors own 60.33% of the stock, while recent insider activity included a pre-planned sale by one executive and a purchase by the chief accounting officer.

Shares of Indivior PLC (NASDAQ:INDV - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $45.1667.

Several research firms have recently issued reports on INDV. Zacks Research downgraded shares of Indivior from a "strong-buy" rating to a "hold" rating in a report on Monday, June 29th. Craig Hallum restated a "buy" rating and set a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. Weiss Ratings raised Indivior from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday, September 4th. Finally, Barclays reduced their price objective on Indivior from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Wednesday, August 5th.

Insiders Place Their Bets

In other Indivior news, insider Christian Heidbreder sold 18,586 shares of the business's stock in a transaction on Friday, July 10th. The shares were sold at an average price of $41.14, for a total value of $764,628.04. Following the sale, the insider owned 209,337 shares of the company's stock, valued at $8,612,124.18. The trade was a 8.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson purchased 1,500 shares of the stock in a transaction on Thursday, August 27th. The stock was acquired at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the acquisition, the chief accounting officer directly owned 27,638 shares in the company, valued at approximately $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.74% of the company's stock.

Institutional Trading of Indivior

Several institutional investors have recently made changes to their positions in INDV. Caitong International Asset Management Co. Ltd increased its stake in Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company's stock valued at $39,000 after acquiring an additional 460 shares during the period. Rockefeller Capital Management L.P. lifted its stake in Indivior by 512.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company's stock worth $46,000 after purchasing an additional 1,076 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in Indivior during the second quarter valued at approximately $63,000. GAMMA Investing LLC acquired a new stake in Indivior during the second quarter valued at approximately $66,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Indivior in the 4th quarter valued at approximately $155,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Trading Down 2.3%

INDV opened at $34.88 on Friday. The business has a 50 day moving average of $37.58 and a 200-day moving average of $36.09. The stock has a market capitalization of $4.12 billion, a price-to-earnings ratio of 12.50 and a beta of 0.82. Indivior has a 1-year low of $22.30 and a 1-year high of $42.81.

Indivior (NASDAQ:INDV - Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The business had revenue of $343.00 million for the quarter. Equities analysts predict that Indivior will post 3.66 EPS for the current year.

Indivior Dividend Announcement

The company also recently announced a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be paid a $8.13 dividend. The ex-dividend date is Friday, October 30th.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose.

The company's key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.